ES2494915T3 - P53 natural como biomarcador para el tratamiento con inhibidores de mTOR en combinación con un agente citotóxico - Google Patents

P53 natural como biomarcador para el tratamiento con inhibidores de mTOR en combinación con un agente citotóxico Download PDF

Info

Publication number
ES2494915T3
ES2494915T3 ES09173161.2T ES09173161T ES2494915T3 ES 2494915 T3 ES2494915 T3 ES 2494915T3 ES 09173161 T ES09173161 T ES 09173161T ES 2494915 T3 ES2494915 T3 ES 2494915T3
Authority
ES
Spain
Prior art keywords
biomarker
natural
treatment
combination
cytotoxic agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES09173161.2T
Other languages
English (en)
Inventor
Iwan Beuvink
Anne Boulay
Heidi Lane
Terence O'reilly
George Thomas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Novartis Forschungsstiftung Zweigniederlassung Friedrich Miescher Institute for Biomedical Research
Novartis Forschungsstiftung
Original Assignee
Novartis AG
Novartis Forschungsstiftung Zweigniederlassung Friedrich Miescher Institute for Biomedical Research
Novartis Forschungsstiftung
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG, Novartis Forschungsstiftung Zweigniederlassung Friedrich Miescher Institute for Biomedical Research, Novartis Forschungsstiftung filed Critical Novartis AG
Application granted granted Critical
Publication of ES2494915T3 publication Critical patent/ES2494915T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G01N33/57575—
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Uso de la determinación de la presencia del gen p53, TP53, natural, en oposición a la ausencia, la deficiencia o la supresión del gen de p53, TP53, o la presencia de un gen de p53, TP53, mutado en la muestra biológica; como un biomarcador para determinar la sensibilidad de una enfermedad proliferativa al tratamiento con un inhibidor de mTOR en combinación con un agente citotóxico.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7

Claims (1)

  1. imagen1
ES09173161.2T 2004-02-23 2005-02-22 P53 natural como biomarcador para el tratamiento con inhibidores de mTOR en combinación con un agente citotóxico Expired - Lifetime ES2494915T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54685604P 2004-02-23 2004-02-23
US546856P 2004-02-23

Publications (1)

Publication Number Publication Date
ES2494915T3 true ES2494915T3 (es) 2014-09-16

Family

ID=34886278

Family Applications (1)

Application Number Title Priority Date Filing Date
ES09173161.2T Expired - Lifetime ES2494915T3 (es) 2004-02-23 2005-02-22 P53 natural como biomarcador para el tratamiento con inhibidores de mTOR en combinación con un agente citotóxico

Country Status (12)

Country Link
US (1) US7749698B2 (es)
EP (2) EP1721007A2 (es)
JP (1) JP5005355B2 (es)
KR (2) KR20120084333A (es)
CN (1) CN1957092B (es)
AU (1) AU2005215910B2 (es)
BR (1) BRPI0507958A (es)
CA (1) CA2555542A1 (es)
ES (1) ES2494915T3 (es)
MX (1) MXPA06009550A (es)
RU (2) RU2429297C2 (es)
WO (1) WO2005080593A2 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO346575B1 (no) * 2005-11-21 2022-10-17 Novartis Ag Anvendelse av 40-O-(2-hydroksyetyl)-rapamycin i behandling av carcinoid eller småøyet celle cancer
EP1996193A2 (en) 2006-03-13 2008-12-03 OSI Pharmaceuticals, Inc. Combined treatment with an egfr kinase inhibitor and an agent that sensitizes tumor cells to the effects of egfr kinase inhibitors
RU2447891C2 (ru) * 2006-04-05 2012-04-20 Новартис Аг Комбинации терапевтических средств, предназначенные для лечения рака
WO2008022256A2 (en) * 2006-08-16 2008-02-21 Blagosklonny Mikhail V Methods and compositions for preventing or treating age-related diseases
DK2245464T3 (en) * 2008-01-25 2017-02-20 Multivir Inc P53 BIOMARKETS
WO2012052758A1 (en) 2010-10-22 2012-04-26 Astrazeneca Ab Response biomarkers for iap antagonists in human cancers
GB2488028A (en) * 2011-02-09 2012-08-15 Astrazeneca Ab mTOR mutants as biomarkers for mTOR inhibitor treatment
BR112013029704A2 (pt) * 2011-05-19 2017-08-29 Toray Industries Agente de indutor de imunidade e uso de um agente indutor de imunidade
RU2509808C1 (ru) * 2012-10-30 2014-03-20 Федеральное государственное бюджетное учреждение науки Институт химической биологии и фундаментальной медицины Сибирского отделения Российской академии наук (ИХБФМ СО РАН) СПОСОБ ОПРЕДЕЛЕНИЯ ЧУВСТВИТЕЛЬНОСТИ КЛЕТОК НЕМЕЛКОКЛЕТОЧНОГО РАКА ЛЕГКИХ К ДЕЙСТВИЮ ПРЕПАРАТОВ, РЕАКТИВИРУЮЩИХ БЕЛОК р53
JP6055430B2 (ja) * 2013-03-29 2016-12-27 三ツ星ベルト株式会社 伝動用ベルト
RU2558860C1 (ru) * 2014-03-28 2015-08-10 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт онкологии" Сибирского отделения Российской академии медицинских наук (ФГБУ "НИИ онкологии" СО РАМН) Способ прогнозирования лимфогенного метастазирования при трипл негативной инвазивной карциноме неспецифического типа молочной железы
WO2020023502A1 (en) 2018-07-23 2020-01-30 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
BR112023001575A2 (pt) * 2020-07-30 2023-04-04 Diadem S P A Método in vitro ou ex vivo para diagnóstico ou prognóstico de doença neurodegenerativa e uso de um kit diagnóstico para implementação do mesmo
CN117942400A (zh) * 2022-10-31 2024-04-30 四川大学 Beclin 1抑制剂在制备治疗p53野生型癌症的药物中的用途
CN117942399A (zh) * 2022-10-31 2024-04-30 四川大学 USP5抑制剂在制备治疗p53野生型癌症的药物中的用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6A (en) * 1836-08-10 Thomas Blanchard Machine for forming end pieces of plank blocks for ships
DK0863984T3 (da) * 1995-11-30 2006-08-28 Univ Texas Fremgangsmåder og præparater til behandling af cancer
DE69907151D1 (de) * 1998-02-18 2003-05-28 Theryte Ltd Krebsbehandlung
EP2269603B1 (en) 2001-02-19 2015-05-20 Novartis AG Treatment of breast tumors with a rapamycin derivative in combination with exemestane

Also Published As

Publication number Publication date
WO2005080593A8 (en) 2006-10-19
EP2228452A1 (en) 2010-09-15
EP1721007A2 (en) 2006-11-15
KR20070022665A (ko) 2007-02-27
RU2385944C2 (ru) 2010-04-10
JP5005355B2 (ja) 2012-08-22
US7749698B2 (en) 2010-07-06
JP2007522812A (ja) 2007-08-16
US20080194613A1 (en) 2008-08-14
RU2008116567A (ru) 2009-11-10
AU2005215910A1 (en) 2005-09-01
MXPA06009550A (es) 2007-03-01
EP2228452B1 (en) 2014-07-16
WO2005080593A2 (en) 2005-09-01
KR101382077B1 (ko) 2014-04-10
RU2006133828A (ru) 2008-03-27
AU2005215910B2 (en) 2008-05-01
KR20120084333A (ko) 2012-07-27
CN1957092B (zh) 2013-04-03
WO2005080593A3 (en) 2005-11-24
CN1957092A (zh) 2007-05-02
CA2555542A1 (en) 2005-09-01
RU2429297C2 (ru) 2011-09-20
BRPI0507958A (pt) 2007-07-17

Similar Documents

Publication Publication Date Title
ES2494915T3 (es) P53 natural como biomarcador para el tratamiento con inhibidores de mTOR en combinación con un agente citotóxico
ES2529147T3 (es) Método para usar los inhibidores de la histona deacetilasa y monitorear biomarcadores en la terapia de combinación
ES2502472T3 (es) Composición adhesiva para su uso en un inmunosensor
ES2665917T3 (es) Endoxifeno para su uso en el tratamiento del cáncer
CY1124426T1 (el) Φαρμακευτικες συνθεσεις οι οποιες περιεχουν νιτρωδες νατριο
ES2527776T3 (es) Biomarcadores para predecir la sensibilidad de células a compuestos inmunomoduladores durante el tratamiento del linfoma no Hodgkin
ES2575152T3 (es) Combinación terapéutica y uso de anticuerpos antagonistas de DLL4 y agentes antihipertensores
CL2008001633A1 (es) Compuestos derivados de pirrolidin-3-carboxamida; composición farmacéutica; y uso comominhibidores de erk para el tratamiento del cancer.
AR059203A1 (es) Composiciones para uso vaginal
EA200701094A1 (ru) Усовершенствованное лечение рака с применением агонистов tlr3
ES2479542T1 (es) Métodos y composiciones para su uso en terapias celulares
ECSP088598A (es) Derivados de piridazinona
MX2020001156A (es) Metodo para el pronostico y tratamiento de metastasis de cancer.
ES2421516T3 (es) Composiciones para tratar el cáncer usando el inhibidor de proteasomas PS-341
AR031455A1 (es) Metodo para determinar un regimen quimioterapeutico basado en la expresion de ercc1
ES2515168T3 (es) Detección y tratamiento de la esquizofrenia
CY1113651T1 (el) Αντιφλεγμονωδη σκευασματα
WO2010028373A3 (en) Methods for diagnosing cancer and determining the overall survival and disease-free survival of cancer patients
CL2012002887A1 (es) Combinación farmacéutica que comprende compuestos derivados de 2,3-dihidroimidazo[1,2-c]quinazolina sustituida, compuestos derivados de n-(2-arilamino)arilsulfonamida y opcionalmente otros agentes farmacéuticos adicionales; kit faramacéutico; método de tratamiento; y su uso para el tratamiento o la profilaxis del cáncer.
CL2007000595A1 (es) Compuestos derivados de piperidina; composicion farmaceutica y uso para el tratamiento y/o profilaxis de enfermedades seleccionadas entre hipertension, insuficiencia cardiaca congestiva e insuficiencia renal entre otras.
ES2601028T3 (es) Método de medición inmunológica para el precursor del péptido liberador de gastrina
CL2014000606A1 (es) Combinacion farmaceutica que comprende al compuesto 2-{2-[(2s)-2-metil-2,3-dihidro-1h-indol-1-il]-2-oxoetil}-6-(morfolin-4-il)pirimidin-4-(3h)-ona y al menos un inhibidor de la via de mapk; composicion farmaceutica; kit farmaceutico; su uso en el tratamiento del cancer.
ES2586116T3 (es) Procedimiento y composición para el tratamiento, la prevención y el diagnóstico de cáncer que contiene células madre de cáncer o derivados de las mismas
SG158133A1 (en) Method for reversing multiple resistance in animal cells
AR076113A1 (es) Metodo o sistema que usa biomarcadores para el seguimiento de un tratamiento